Objective: Magnesium sulfate (MgSO 4 ) is the most commonly used tocolytic agent in the US and is also employed as a prophylactic agent against seizures in pre-eclamptic women. MgSO 4 crosses the placenta and its concentration in the newborn usually exceeds that of maternal levels. The purpose of this study was to explore the relationship between antenatal exposure to MgSO 4 and the incidence of patent ductus arteriosus (PDA) in extremely low birth weight infants.
Introduction
Magnesium sulfate (MgSO 4 ) is the most commonly used tocolytic agent in the US. 1 It is also used as a prophylactic agent against seizures in pre-eclamptic women. MgSO 4 crosses the placenta by passive or facilitated transport and its concentration in newborn infants usually exceeds maternal levels and leads to hypermagnesemia, with cord concentrations 70 to 100% higher than maternal levels. 2, 3 In recent years, several studies using various different methodological approaches have proved inconclusive concerning the possible relationship between in utero exposure to MgSO 4 and perinatal morbidity in extremely low birth weight infants (ELBW). Other observational studies have disputed a role for prenatal MgSO 4 as a neuroprotective agent. [4] [5] [6] [7] Initial studies evaluating the effects of MgSO 4 on neonates were undertaken in pregnancies complicated with pregnancy-induced hypertension and preterm labor in which MgSO 4 was used for a relatively short period of time. In these studies, complications related to MgSO 4 were rare. Neonates exposed to high doses or prolonged administration of MgSO 4 , on the other hand, were reported to have more complications.
In the Magnesium and Neurologic Endpoints Trial adverse outcomes were found to be associated with magnesium exposure in a dose-related fashion. Infants who had intraventricular hemorrhage (IVH) were more likely to have been delivered to mothers with higher serum ionized magnesium levels. 8 These data suggest that there is a therapeutic window requiring dose limitations above which toxicity may increase. 9 Magnesium plays an important role in the regulation of vascular tone. MgSO 4 acts as a calcium chanel blocker that antagonizes calcium ion entry into the smooth muscle cells, thus promoting vasodilatation. Extracellular magnesium influences intracellular calcium mobilization of the vascular muscles cells and also endothelial cells, and enhances PGI production; both of the mechanisms can contribute to the delayed closure of the ductus arteriosus. 10 In extremely premature infants, acute morbidity is closely related to rapid vascular changes occurring after birth. However, little is known about the cardiovascular effects of MgSO 4 in these infants. The purpose of this study was to explore the relationship between antenatal exposure to MgSO 4 and the incidence of patent ductus arteriosus (PDA) in ELBW infants.
Methods
A cohort study was conducted to compare the outcomes of ELBW infants whose mothers received MgSO 4 for either tocolysis or seizure prophylaxis and a control group of infants whose mothers did not receive MgSO 4 . The study population included neonates with birth weights between 500 and 1000 g, born at the University of Miami/Jackson Memorial Medical Center (UM/JMMC) from January 1995 to December 2004 and admitted to the Neonatal Intensive Care Unit.
Perinatal information was prospectively collected as part of a larger study approved by the University of Miami Committee for the Protection of Human Subjects in Research. The study met the criteria for waiver of informed consent. Data from the maternal and newborn records were collected and abstracted into standardized forms by a trained research nurse using preestablished definitions developed by the investigators and described in the study manual of operations. Maternal and neonatal factors included race, gender, mode of delivery, gestational age at delivery, antenatal exposure to steroids and presence of chorioamnionitis.
Antenatal exposure to MgSO 4 consisted of a bolus infusion of 4 to 6 g followed by 2 g every hour. The total dose of MgSO 4 administered over the entire hospitalization was calculated and recorded using detailed nursing notes and charts.
The primary outcome variable was PDA. The diagnosis of PDA was confirmed by echocardiogram in infants with suspected PDA based on clinical criteria that included cardiac murmur, bounding pulses, respiratory deterioration, increased oxygen requirements, or increased CO 2 retention, wide differential blood pressure, hypotension, decreased urine output and metabolic acidosis.
Statistical analysis
The incidence of PDA was compared in infants exposed to MgSO 4 with those not exposed, and between infants exposed to different maternal doses of MgSO 4 .
Univariate analyses for maternal and neonatal variables were performed according to gender, race, birth weight, gestational age, presence of chorioamnionitis, exposure to maternal antibiotics, use of antenatal steroids and mode of delivery. Because the different incidence of PDA depending on the gestational age, analysis of the data stratified by gestational age (<26 vs X26 weeks) was conducted. Additional analysis of subgroups stratified by the indication for the use of MgSO 4 was also performed. To control for possible confounding variables, multivariate logistic regression analysis was used to estimate the effect of exposure to MgSO 4 whereas taking into account the effect of other possible confounding variables. Covariables included: gestational age or birth weight, race, gender, mode of delivery, antenatal steroids, presence of chorioamnionitis and indication for use of MgSO 4 .
BMDP statistical software was used for data analysis. (BMDP statistical software. Version PC90. Los Angeles, CA 90097-2514.1990).
Results
A total of 954 neonates with birth weights between 500 and 1000 g, born at UM/JMMC and surviving for more than 3 days were included in the study. There were 13 infants with missing data that were excluded from the analysis. There were 546 (58%) neonates exposed to MgSO 4 and 395 (42%) not exposed. The indications for the use of MgSO 4 was tocolisis in 395 cases (72%) and preeclampsia in 151 cases (28%). Race, gender and the proportion of infants <26 weeks and small for gestational age were not different between groups (Table 1 ). The MgSO 4 exposed-infants were less likely to have been exposed to chorioamnionitis (9 vs 23%) ( Table 1) . Antenatal steroids were used more commonly in those infants exposed to MgSO 4 (95 vs 73%) ( Table 1) .
The incidence of PDA was significantly higher in the group of infants exposed to MgSO 4 compared with the controls (67 vs. 60%, P ¼ 0.0178). When stratified by gestational age the differences were significant only in the group of infants with a gestational age X26 weeks (58 vs. 49%, P ¼ 0.0399). Moreover, in these infants the incidence of PDA increased concomitantly with the dose of MgSO 4 given to the mother (Figure 1 ). The subgroup of infants whose mothers were given MgSO 4 for seizure prophylaxis have a higher proportion of infants X26 weeks that the subgroup of infants whose mothers received MgSO 4 for tocolysis (74 vs 47%, P<0.05) and, consequently a lower incidence of PDA (51 vs 72%, P<0.01). A similar dose-related tendency towards a higher incidence of PDA was observed within the subgroups on infants exposed to MgSO 4 used for tocolysis or pre-eclampsia in the group of infants with gestational age X26 weeks (Figure 2) . Most of the first episodes of PDA occurred within the first week after birth (85% in the MgSO 4 -exposed group vs 87% in the nonexposed group). Duration of PDA Magnesium sulfate and patent ductus arteriosus T del Moral et al was 1 week or less in 52% of the cases (50% in the MgSO 4 exposure group vs 53% in the control group). The need for surgical PDA ligation was not different between the two groups (30% of PDA needed to be ligated in the MgSO 4 exposed group vs 34% in the control group). Logistic regression analysis showed that after controlling for confounding variables there was an increased risk of PDA in infants exposed to MgSO 4 . In infants with a gestational age of X26 weeks, there was an increased risk of PDA with higher cumulative maternal dose of MgSO 4 ( Figure 3) .
Mortality (18% in the MgSO 4 exposed group vs 22% in the control) did not differ between groups and the incidence of grade III and IV IVH (12 vs 13%) and PVL (2.3 vs 1.1%) was also similar between infants exposed and not exposed to MgSO 4 .
Discussion
The main finding of this study is that antenatal exposure to MgSO 4 in this cohort of ELBW infants is associated with a higher risk of PDA. This effect is dose-related and more evident in the more mature infants (X26 weeks).
Animal studies have shown that calcium-channel blockers such as verapamil administered immediately after birth inhibit the spontaneous constriction of the ductus arteriosus.
11 MgSO 4 is also essential for any enzymatic reaction requiring ATP. High magnesium concentrations competitively inhibit several calciumdependent reactions, resulting in the dilatation of resistance vessels. Echocardiography and Doppler studies in pregnant women have shown a depressed right ventricular cardiac function and lower pulsatility index in the middle cerebral artery in fetuses after prolonged exposure to MgSO 4 compared with normal fetuses. 12 Our results are consistent with a previous study with a small number of infants, in which infants with PDA had significantly higher levels of serum MgSO 4 at birth. 13 An interesting finding of this study is the increased risk of PDA with higher doses of MgSO 4 in infants of X26 weeks gestational age. Animal studies have demonstrated that there is a developmental change in the voltage-dependent Ca channels which can affect the magnesium-induced relaxation of vessels and that this may play an important role in the developmental changes of vasodilatation induced by MgSO 4 in the rabbit lung.
14 These animal studies suggest that there may be a developmental increase in the dilator effect of MgSO 4 , which could well explain the more evident effect of MgSO 4 exposure in the more mature infants. The importance of the cumulative total dose of MgSO 4 administered to the mother has been suggested elsewhere in the literature. 8, 15 In randomized trials reporting no excess of perinatal mortality the dose of MgSO 4 was not computed. Some of the clinical trials of MgSO 4 used much lower cumulative dosages and so they do not answer the question as to whether high magnesium doses contribute to perinatal morbidity. In the latest trial to test the use of MgSO 4 for neuroprotection the dose was relatively low (median 10.5 g). 16 In two randomized trials, 17, 18 however, exposure to 50 g or higher doses has been found to be associated with increased mortality among infants. A case-control study demonstrated increased mortality when the cumulative doses of MgSO 4 sulfate was greater than 48 g, which is equivalent to one day exposure to MgSO 4 at the common tocolytic dose. 15 A meta-analysis also showed higher mortality in the subgroup of infants that were exposed to a higher dose. 19 Therefore, it may be difficult to detect the effect on perinatal morbidity if the analyses do not consider the total exposure to MgSO 4 .
Studies investigating the perinatal effects of high-dose tocolytic MgSO 4 are scarce. This study addresses the association between perinatal morbidity and MgSO 4 doses in a large population of extreme premature infants. The results suggest that the effects of exposure to MgSO 4 are related to the total amount of MgSO 4 given to the mother.
One limitation of the study is the retrospective nature of the analysis. Although the data allowed the computation of the total dose of MgSO 4 administered to the mother, no information concerning the time between the last dose of MgSO 4 and delivery was available. Differences in this interval may affect the levels of MgSO 4 in the newborn.
In conclusion, the findings of this study raise concerns about the use of MgSO 4 as a tocolytic agent, especially in high doses. The goal of tocolytic therapy should be to prevent preterm birth with a concomitant reduction in associated neonatal morbidity. Therefore, bearing in mind that no relevant tocolytic effect of MgSO 4 has been established and that there is a lack of evidence for any benefit to the newborn infant, 16 MgSO 4 should be used with caution. The potential use of lower doses of MgSO 4 for cerebral protection is presently being addressed in two randomized clinical trials.
